<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIPYRIDAMOLE- dipyridamole tablet, film coated </strong><br>NCS HealthCare of KY, Inc dba Vangard Labs<br></p></div>
<h1>DIPYRIDAMOLE TABLETS, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8b0faadf-5db0-484d-aa31-867b48ed74aa"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Revised NOVEMBER 2005</p>
<p>11001008</p>
<p><span class="Bold">Rx </span><span class="Bold">only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_509c6c8d-c0a7-4b08-9ee0-e10efa40d8f0"></a><a name="section-2"></a><p></p>
<h1>Description:</h1>
<p class="First">Dipyridamole is a platelet inhibitor chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido [5,4-<span class="Italics">d</span>] pyrimidine -2,6 - diyl) dinitrilo] tetraethanol. It has the following structural formula: </p>
<div class="Figure"><img alt="Dipyridamole Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcf785b2-e923-43bf-93bb-00a9501479f4&amp;name=dipyridamole-1.jpg"></div>
<p>                                        C<span class="Sub">24</span>H<span class="Sub">40</span>N<span class="Sub">8</span>O<span class="Sub">4</span>                                      M.W. 504.63</p>
<p>Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water.</p>
<p>Dipyridamole Tablets, USP for oral administration contain:</p>
<p><span class="Bold">Active Ingredient: </span>25 mg, 50 mg, and 75 mg; dipyridamole USP 25 mg, 50 mg and 75 mg, respectively.</p>
<p><span class="Bold">Inactive Ingredients:</span> Colloidal silicon dioxide, hypromellose, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, propylene glycol, stearic acid, sodium starch glycolate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_37b98b4f-8ddc-42d6-af7d-5e26cd414c3a"></a><a name="section-3"></a><p></p>
<h1>Clinical Pharmacology:</h1>
<p class="First">It is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormally shortened platelet survival time, is a significant factor in thromboembolic complications occurring in connection with prosthetic heart valve replacement.</p>
<p>Dipyridamole tablets have been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner.</p>
<p>In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> by 62 to 91% compared to warfarin treatment alone. The incidence of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> in patients receiving the combination of dipyridamole tablets and warfarin ranged from 1.2 to 1.8%. In three additional studies involving 392 patients taking dipyridamole tablets and coumarin-like anticoagulants, the incidence of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> ranged from 2.3 to 6.9%.</p>
<p>In these trials, the coumarin anticoagulant was begun between 24 hours and 4 days postoperatively, and the dipyridamole tablets were begun between 24 hours and 10 days postoperatively. The length of follow-up in these trials varied from 1 to 2 years.</p>
<p>Dipyridamole tablets do not influence <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or activity measurements when administered with warfarin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6599527a-0c30-4871-8901-bfc89e6593a6"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action:</h2>
<p class="First">Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes <span class="Italics">in vitro</span> and <span class="Italics">in vivo;</span> the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to 1.9 mcg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A<span class="Sub">2</span>-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).</p>
<p>Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7a547d5e-8311-439e-9263-d22dbf74f09c"></a><a name="section-3.2"></a><p></p>
<h2>Hemodynamics:</h2>
<p class="First">In dogs intraduodenal doses of dipyridamole of 0.5 to 4 mg/kg produced dose-related decreases in systemic and coronary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> leading to decreases in systemic blood pressure and increases in coronary blood flow. Onset of action was in about 24 minutes and effects persisted for about 3 hours.</p>
<p>Similar effects were observed following IV dipyridamole in doses ranging from 0.025 to 2 mg/kg.</p>
<p>In man the same qualitative hemodynamic effects have been observed. However, acute intravenous administration of dipyridamole may worsen regional myocardial perfusion distal to partial occlusion of coronary arteries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d223ab77-e0c2-4431-993e-5bc4198ca707"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics and Metabolism:</h2>
<p class="First">Following an oral dose of dipyridamole tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of dipyridamole tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyridamole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_776e18e5-1a89-448f-9fef-9a980cd6df49"></a><a name="section-4"></a><p></p>
<h1>Indications and Usage:</h1>
<p class="First">Dipyridamole Tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_33eacd3c-11ca-4306-bddc-f593f0f314c5"></a><a name="section-5"></a><p></p>
<h1>Contraindications:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to dipyridamole and any of the other components.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_7a9e0671-22c2-4d61-b731-a05439453f77"></a><a name="section-6"></a><p></p>
<h1>Precautions:</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_6a95dd76-3588-4bfa-8774-cdd00b3f2937"></a><a name="section-6.1"></a><p></p>
<h2>General:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1e2b6dd3-6fc7-4d7a-a10e-40ebbced1d31"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>:</h3>
<p class="First">Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or recently sustained <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> may be aggravated in patients with underlying <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> who are receiving dipyridamole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_51170694-bd7c-4151-b100-c082676fb29f"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</h3>
<p class="First">Elevations of hepatic enzymes and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported in association with dipyridamole administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_61638aba-09db-4244-927c-cece6bf49034"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</h3>
<p class="First">Dipyridamole should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> since it can produce peripheral vasodilation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_b1ef1a17-b3e0-4f25-8d17-bbd770a0281a"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">Dipyridamole has been associated with elevated hepatic enzymes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3295b736-8855-48b4-898f-958e1aa6f7c3"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets. The following information was obtained from the literature.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_76549ecc-405b-4593-8ec9-ca11401dbf46"></a><a name="section-6.3.1"></a><p></p>
<h3>Adenosine:</h3>
<p class="First">Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d828d518-3af7-4a19-881b-ad0e35295b8c"></a><a name="section-6.3.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">Cholinesterase</span> Inhibitors:</h3>
<p class="First">Dipyridamole may counteract the anticholinesterase effect of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors, thereby potentially aggravating <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_b9a529f3-f851-4430-9d21-29d16c1a30a3"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m<span class="Sup">2</span> basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. Mutagenicity tests of dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m<span class="Sup">2</span> basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_a341d731-74fe-4d1f-9b2f-75cc4dcc3a39"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_405470f8-c39a-4083-abf8-0c1a6fe62723"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fc20177f-9d1e-41c9-b78c-338e3ed4d252"></a><a name="section-6.5.1.1"></a><p></p>
<h4>Pregnancy Category B:</h4>
<p class="First">Reproduction studies have been performed in mice, rabbits and rats at oral dipyridamole doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m<span class="Sup">2</span> basis) and have revealed no evidence of harm to the fetus due to dipyridamole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, dipyridamole should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_3ec12cf7-e338-47f8-b2da-9033552f98ea"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">As dipyridamole is excreted in human milk, caution should be exercised when dipyridamole tablets are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_0373c6bb-c059-4757-b508-41532b1039e4"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in the pediatric population below the age of 12 years has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_13bfa7c8-6184-4667-826b-d4b84d872150"></a><a name="section-7"></a><p></p>
<h1>Adverse Reactions:</h1>
<p class="First">Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo:</p>
<table>
<caption><span>Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <span class="Bold">Adverse Reaction</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> <span class="Bold">Dipyridamole Tablets/ Warfarin</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"> <p class="First"><span class="Bold">Placebo/</span></p>
<span class="Bold">Warfarin</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> Number of Patients</td>
<td class="Botrule Rrule" align="center" valign="top"> 147</td>
<td class="Botrule Rrule" align="center" valign="top"> 170</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top"> 13.6%</td>
<td class="Botrule Rrule" align="center" valign="top"> 8.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal distress</span></td>
<td class="Botrule Rrule" align="center" valign="top"> 6.1%</td>
<td class="Botrule Rrule" align="center" valign="top"> 3.5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="top"> 2.3%</td>
<td class="Botrule Rrule" align="center" valign="top"> 0.0%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center" valign="top"> 2.3%</td>
<td class="Botrule Rrule" align="center" valign="top"> 1.1%</td>
</tr>
</tbody>
</table>
<p>Other reactions from uncontrolled studies include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. In addition, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> has been reported rarely, and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication.</p>
<p>When dipyridamole tablets were administered concomitantly with warfarin, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during or after surgery has been observed.</p>
<p>In post-marketing reporting experience, there have been rare reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>), <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">larynx edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_7fb569aa-7bcb-4238-9586-af5ab5fff83d"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">In case of real or suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, feeling of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> may occur. A <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> might also be observed.</p>
<p>Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e508f054-0033-474f-b7ec-d705e3db43f1"></a><a name="section-9"></a><p></p>
<h1>Dosage and Administration:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cb0a55df-ec13-453c-a340-7088399f416f"></a><a name="section-9.1"></a><p></p>
<h2>Adjunctive Use in Prophylaxis of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span> after Cardiac Valve Replacement:</h2>
<p class="First">The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_49c6194c-4108-4fc1-ad65-ee3c0c05c1e1"></a><a name="section-10"></a><p></p>
<h1>How Supplied:</h1>
<p class="First">Dipyridamole Tablets, USP are available as:</p>
<p>25 mg: White, round, film-coated, unscored tablets. Debossed with stylized <span class="Bold">b</span> on one side and 252 on the other side. </p>
<p>50 mg: White, round, film-coated, unscored tablets. Debossed with stylized <span class="Bold">b</span> on one side and 285 on the other side. Available in blistercards of: 30 Tablets NDC 0615-1573-39</p>
<p>75 mg: White, round, film-coated, unscored tablets. Debossed with BARR on one side and 286 on the other side. </p>
<p>Dispense with a child-resistant closure in a tight, light-resistant container.</p>
<p>Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_459f1ba7-6b8a-4d99-b139-7e1ce5acff36"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MANUFACTURED BY</span><br><span class="Bold">BARR LABORATORIES, INC.</span><br><span class="Bold">POMONA, NY 10970</span></p>
<p>Revised NOVEMBER 2005 (v.4)<br>BR - 0252, 0285, 0286</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_32b2e053-bc50-49cc-8b3d-7569ebea0b04"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Principal Display Panel- Dipyridamole Tablets, USP 50mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dcf785b2-e923-43bf-93bb-00a9501479f4&amp;name=dipyridamole-2.jpg"><p class="MultiMediaCaptionNotCentered"></p> Dipyridamole Tabs, USP 50mg</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIPYRIDAMOLE 		
					</strong><br><span class="contentTableReg">dipyridamole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0615-1573(NDC:0555-0285)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIPYRIDAMOLE</strong> (DIPYRIDAMOLE) </td>
<td class="formItem">DIPYRIDAMOLE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;285</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0615-1573-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA087716</td>
<td class="formItem">01/23/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NCS HealthCare of KY, Inc dba Vangard Labs
							(050052943)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NCS HealthCare of KY, Inc dba Vangard Labs</td>
<td class="formItem"></td>
<td class="formItem">050052943</td>
<td class="formItem">RELABEL(0615-1573), REPACK(0615-1573)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f26e686a-aa0a-4e50-a492-d25a3fe8c201</div>
<div>Set id: dcf785b2-e923-43bf-93bb-00a9501479f4</div>
<div>Version: 3</div>
<div>Effective Time: 20120917</div>
</div>
</div> <div class="DistributorName">NCS HealthCare of KY, Inc dba Vangard Labs</div></p>
</body></html>
